Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, September 1, 2016

Stroke Prevention for Patients With Atrial Fibrillation Similar With Warfarin, Newer Oral Anticoagulants

Didn't answer the outstanding question that there is no reversal agent for the newer ones. How many died or had negative outcomes because of no reversal agent? Can't these people even think of the correct questions to answer while doing research? Must I do everything? Think and wipe their ass?
http://dgnews.docguide.com/stroke-prevention-patients-atrial-fibrillation-similar-warfarin-newer-oral-anticoagulants?
An observational study comparing new oral anticoagulants with warfarin found stroke prevention to be similar, but the newer anticoagulants provided reduced intracranial bleeding, according to a study presented here at the 2016 Annual Meeting of the European Society of Cardiology (ESC).
The study included 43,299 patients with atrial fibrillation who were recruited from Danish nationwide administrative registries. In the cohort, 42% of patients were taking warfarin, 29% were taking dabigatran, 16% were on apixaban, and 13% were taking rivaroxaban.
“There has been a need to investigate safety and effectiveness of new oral anticoagulants versus warfarin in a ‘real world’ population and our Danish registries provide this opportunity,” said Laila Staerk, MD, Herlev and Gentofte University Hospitals, Herlev, Denmark.
Efficacy outcomes were stroke and all-cause mortality. Patients were followed until outcome, death, switch or discontinuation of initiated anticoagulant treatment, emigration, or study end.
During treatment, stroke occurred in 1,850 (4%) patients and there were 6,477 (15%) deaths.
The absolute stroke risk at 1 year of initiating treatment was similar for each of the 4 groups, at 2.01% for warfarin, 2.12% for dabigatran, 2.06% for rivaroxaban, and 2.46% for apixaban.
Absolute risk of all-cause mortality at 1 year after initiation of warfarin was 18.0%, dabigatran 11.5%, rivaroxaban 14.7%, and apixaban 14.9%.
Standardised absolute risk of intracranial bleeding at 1 year was reduced in patients who were taking the newer oral anticoagulants. Absolute risk was 0.60% for warfarin, 0.26% for dabigatran (P =0.05 vs warfarin), 0.47% for rivaroxaban, and 0.40% for apixaban (P = .05 vs warfarin).
“Among patients with atrial fibrillation who were new users of oral anticoagulation, while treatment with [these newer drugs] was not associated with a significantly lower risk of stroke, treatment with dabigatran and apixaban was associated with a significantly lower risk of intracranial bleeding compared with warfarin,” said Dr. Staerk.
[Presentation title: Stroke and All-Cause Mortality With Non-Vitamin K Antagonist Oral Anticoagulation Versus Warfarin in Atrial Fibrillation: a Nationwide Study. Abstract 1875]

No comments:

Post a Comment